These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12911871)

  • 1. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: part I. Differences due to the acquisition of HIV-infection.
    Neumann T; Woiwoid T; Neumann A; Miller M; Ross B; Volbracht L; Brockmeyer N; Gerken G; Erbel R
    Eur J Med Res; 2003 Jun; 8(6):229-35. PubMed ID: 12911871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences.
    Neumann T; Woiwod T; Neumann A; Ross B; Von Birgelen C; Volbracht L; Brockmeyer NH; Gerken G; Erbel R
    Eur J Med Res; 2004 Feb; 9(2):55-60. PubMed ID: 15090290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART.
    Berg T; Zdunek D; Stalke J; Dupke S; Baumgarten A; Carganico A; Hess G
    Eur J Med Res; 2007 Apr; 12(4):152-60. PubMed ID: 17509959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
    Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
    AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.
    Law MG; Friis-Møller N; El-Sadr WM; Weber R; Reiss P; D'Arminio Monforte A; Thiébaut R; Morfeldt L; De Wit S; Pradier C; Calvo G; Kirk O; Sabin CA; Phillips AN; Lundgren JD;
    HIV Med; 2006 May; 7(4):218-30. PubMed ID: 16630034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial function in HIV-infected patients with low or mild cardiovascular risk.
    Blanco JJ; García IS; Cerezo JG; de Rivera JM; Anaya PM; Raya PG; García JG; López JR; Hernández FJ; Rodríguez JJ
    J Antimicrob Chemother; 2006 Jul; 58(1):133-9. PubMed ID: 16702174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study.
    Glass TR; Ungsedhapand C; Wolbers M; Weber R; Vernazza PL; Rickenbach M; Furrer H; Bernasconi E; Cavassini M; Hirschel B; Battegay M; Bucher HC;
    HIV Med; 2006 Sep; 7(6):404-10. PubMed ID: 16903986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk.
    Masiá M; Bernal E; Padilla S; García N; Escribano JC; Martínez E; Gutiérrez F
    J Antimicrob Chemother; 2009 Sep; 64(3):589-98. PubMed ID: 19625372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study.
    De Socio GV; Parruti G; Quirino T; Ricci E; Schillaci G; Adriani B; Marconi P; Franzetti M; Martinelli C; Vichi F; Penco G; Sfara C; Madeddu G; Bonfanti P;
    J Infect; 2008 Jul; 57(1):33-40. PubMed ID: 18436307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
    Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
    Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
    Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
    HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score.
    Mangili A; Gerrior J; Tang AM; O'Leary DH; Polak JK; Schaefer EJ; Gorbach SL; Wanke CA
    Clin Infect Dis; 2006 Dec; 43(11):1482-9. PubMed ID: 17083026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity.
    Jung O; Bickel M; Ditting T; Rickerts V; Welk T; Helm EB; Staszewski S; Geiger H
    Nephrol Dial Transplant; 2004 Sep; 19(9):2250-8. PubMed ID: 15238630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is estimated cardiovascular risk higher in HIV-infected patients than in the general population?
    De Socio GV; Martinelli L; Morosi S; Fiorio M; Roscini AR; Stagni G; Schillaci G
    Scand J Infect Dis; 2007; 39(9):805-12. PubMed ID: 17701720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients - part III: age differences.
    Neumann T; Woiwod T; Neumann A; Miller M; Von Birgelen C; Volbracht L; Esser S; Brockmeyer N; Gerken G; Erbel R
    Eur J Med Res; 2004 May; 9(5):267-72. PubMed ID: 15257881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference.
    Juonala M; Viikari JS; Hutri-Kähönen N; Pietikäinen M; Jokinen E; Taittonen L; Marniemi J; Rönnemaa T; Raitakari OT
    J Intern Med; 2004 Apr; 255(4):457-68. PubMed ID: 15049880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High protein diets decrease total and abdominal fat and improve CVD risk profile in overweight and obese men and women with elevated triacylglycerol.
    Clifton PM; Bastiaans K; Keogh JB
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):548-54. PubMed ID: 19179060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.